background
human
metapneumoviru
hmpv
associ
acut
respiratori
tract
infect
arti
patient
age
group
object
evalu
perform
rapid
antigen
test
hmpv
genotyp
studi
design
frozen
nasopharyng
aspir
individu
arti
analyz
presenc
hmpv
antigen
use
enzym
immunoassay
eia
biotrin
ltd
result
hmpv
eia
show
sensit
specif
posit
predict
valu
neg
predict
valu
compar
viral
cultur
rtpcr
conclus
biotrin
hmpv
eia
conveni
altern
cell
cultur
detect
hmpv
excel
specif
human
metapneumoviru
hmpv
member
pneumovirina
subfamili
paramyxovirida
famili
recent
recogn
lead
caus
acut
respiratori
tract
infect
arti
children
elderli
subject
comorbid
condit
chronic
obstruct
pulmonari
diseas
asthma
immunosuppress
frequent
use
diagnost
method
hmpv
consist
revers
transcript
rt
pcr
assay
perform
directli
clinic
sampl
isol
cell
cultur
follow
viru
confirm
rtpcr
howev
rtpcr
assay
commerci
avail
viral
growth
fastidi
restrict
limit
number
cell
line
cell
incub
time
week
typic
requir
hmpv
cytopath
effect
seen
cell
cultur
recent
direct
fluoresc
antibodi
stain
respiratori
cell
nasopharyng
aspir
npa
report
use
monoclon
antibodi
offer
rapid
altern
molecular
assay
hmpv
detect
report
compar
perform
convent
cell
cultur
commerci
enzym
immunoassay
eia
detect
hmpv
antigen
npa
subject
arti
specif
rtpcr
assay
use
resolv
discrep
result
sensit
analysi
set
hmpvposit
npa
collect
identifi
use
viral
cultur
cell
confirm
rtpcr
cell
cultur
supernat
contain
hmpv
nucleoprotein
gene
specif
analysi
set
hmpvneg
npa
select
cell
cultur
neg
hmpv
contain
virus
detect
cell
cultur
rtpcr
sampl
randomli
select
one
per
patient
base
avail
materi
test
blind
manner
sampl
frozen
c
period
year
test
hmpv
eia
recommend
manufactur
biotrin
intern
ltd
dublin
ireland
cell
cultur
done
prior
freez
repeat
part
current
studi
hmpv
eia
antigen
captur
assay
qualit
detect
hmpv
antigen
human
respiratori
specimen
well
eia
plate
coat
uniqu
combin
monoclon
antibodi
matrix
fusion
protein
viru
extract
buffer
use
pretreat
sampl
addit
assay
specif
hmpv
antigen
present
bind
monoclon
antibodi
coat
surfac
plate
volum
l
respiratori
secret
duplic
test
test
follow
wash
step
peroxidaselabel
antihmpv
monoclon
antibodi
ad
bound
antigenantibodi
complex
detect
addit
tetramethylbenzidin
substrat
tmb
turn
blue
presenc
peroxidas
stabl
yellow
end
product
achiev
addit
stop
reagent
total
incub
time
assay
h
min
presenc
absenc
hmpv
determin
relat
calcul
cut
valu
cov
latter
determin
ad
constant
valu
optic
densiti
unit
determin
manufactur
assay
develop
mean
neg
control
valu
assay
data
comparison
differ
assay
run
facilit
use
index
valu
iv
wherebi
sampl
absorb
express
rel
assay
cov
iv
indic
sampl
neg
posit
respect
equivoc
indic
iv
rang
inclus
discord
hmpv
result
cell
cultur
hmpv
eia
resolv
use
realtim
rtpcr
assay
total
rna
extract
npa
use
qiaamp
viral
rna
minikit
qiagen
mississauga
ontario
canada
complementari
cdna
synthes
use
random
primer
omniscript
revers
transcriptas
kit
qiagen
cdna
amplifi
use
previous
describ
realtim
pcr
assay
sybr
r
green
taq
readymix
tm
sigma
st
loui
mo
lightcycl
instrument
roch
diagnost
laval
quebec
canada
cycl
condit
slightli
modifi
includ
initi
denatur
step
c
follow
cycl
c
c
c
nucleotid
sequenc
select
hmpv
nucleoprotein
amplicon
determin
autom
dna
sequenc
abi
prism
appli
biosystem
foster
citi
ca
base
cell
cultur
result
npa
found
posit
hmpv
wherea
neg
latter
posit
anoth
viru
addit
npa
found
posit
respiratori
virus
multiplex
rtpcr
assay
also
includ
studi
thu
total
virus
use
specif
analysi
includ
human
respiratori
syncyti
virus
parainfluenza
virus
adenovirus
coronaviru
influenza
viru
rhinoviru
herp
simplex
viru
measl
viru
coinfect
virus
hmpv
among
npa
posit
hmpv
cell
cultur
hmpv
eia
posit
neg
equivoc
rtpcr
test
discord
result
reveal
eiaequivoc
well
eianeg
npa
fact
true
posit
tabl
hand
hmpv
eia
neg
hmpvneg
npa
cell
cultur
rtpcr
one
rhinovirusenteroviru
rtpcrposit
sampl
found
equivoc
hmpv
eia
confirm
hmpvneg
rtpcr
tabl
perform
biotrin
hmpv
eia
establish
respect
cell
cultur
complement
use
rtpcr
discord
result
tabl
accord
gold
standard
count
eia
equivocalrtpcrposit
result
true
posit
hmpv
eia
sensit
specif
posit
predict
valu
neg
predict
valu
unavail
specimen
repeat
test
exclus
sampl
equivoc
result
would
result
valid
estim
test
perform
case
hmpv
eia
sensit
ci
specif
ten
hmpv
sampl
identifi
posit
cell
cultur
rtpcr
detect
hmpv
eia
discrep
probabl
relat
lack
detect
specif
hmpv
genotyp
sinc
identifi
hmpv
type
b
eia
tabl
hand
discrep
result
correl
viral
load
low
viral
load
might
limit
detect
eia
thu
mean
rtpcr
cycl
threshold
c
valu
obtain
select
eia
positivertpcr
posit
sampl
eia
equivocalrtpcr
posit
sampl
eia
negativertpcr
posit
sampl
respect
tabl
rule
possibl
viral
degrad
two
sampl
origin
cellcultur
posit
found
neg
eia
rtpcr
subsequ
test
sever
year
later
develop
sensit
specif
antigen
method
import
rapid
diagnosi
respiratori
viral
infect
rtpcr
consid
method
choic
hmpv
detect
due
slow
replic
viru
cell
line
recent
unavail
rapid
antigen
detect
method
howev
inhous
molecular
method
requir
expens
laboratori
equip
care
train
personnel
despit
lower
sensit
compar
rtpcr
biotrin
hmpv
eia
rapid
less
expens
highli
specif
method
detect
hmpv
clinic
sampl
use
microbiolog
laboratori
importantli
biotrin
hmpv
eia
detect
major
hmpv
genotyp
b
patient
differ
age
one
limit
studi
use
frozen
npa
sampl
sinc
cycl
freez
thaw
may
lead
antigen
degrad
potenti
affect
antigen
detect
thu
may
underestim
true
sensit
eia
test
hand
frozen
sampl
provid
us
opportun
test
differ
hmpv
genotyp
collect
sever
year
anoth
caveat
gener
equivoc
result
eia
test
impli
need
retest
specimen
altern
method
rtpcr
take
anoth
sampl
eia
test
feasibl
studi
addit
prospect
studi
need
evalu
assay
use
fresh
respiratori
sampl
type
specimen
